Next Phase Newsletter

By Caitlin Dolegowski, Marketing Manager, LSN

RESI Boston, June 5-7 is rapidly approaching, and the partnering platform opens next Monday, May 15. This hybrid conference enables attendees to book meetings either in person on Monday, June 5, or virtually, June 6-7.  The LSN Partnering Platform offers startups the opportunity to search for and identify investors that are a fit for them based on sector, indication, stage of development and other criteria. Successful partnering takes a lot of work, and the companies that book the most meetings send, on average, over 100 meeting requests to relevant investors, followed by frequent follow-ups. We will be offering a free partnering tutorial next week to provide you with helpful insight into making the most of your time at RESI.

There is still time to register for RESI Boston, June 5-7 and meet with 350+ active investors in the life science industry.

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

RESI Boston during BIO week is just a few weeks away. We’ve already told you about the opportunity to meet with 350+ investors and licensing partners and amazing panels and workshops, but you will also be able to meet with some top service providers who may have just the product or service your company needs or will need in the future. RESI is the conference for early-stage partnering, where you can make connections that are focused on this space that you won’t find at other conferences that are geared toward later stage activities.

Here are some of the companies you can meet in the RESI Exhibition Hall this June.

See you in Boston! REGISTER HERE

By Momo Yamamoto, Investor Research Analyst, LSN

Time is flying by, and there is only a month left until RESI Boston! As a refresher, RESI Boston will be a 3-day hybrid conference, taking place on June 5^th – 7^th. June 5^th will be in-person at the Westin Copley Place, featuring Innovator’s Pitch Challenge (IPC) sessions, 7 investor panels, and educational workshops followed by all-day virtual partnering on June 6^th – 7^th.

Life Science Nation is excited to announce the 20+ panelists who have been selected to speak on our investor panels at RESI Boston. Panel topics include: Big Pharma, Women’s Health, Cell & Gene Therapy, Corporate VC, CNS Diseases, Medtech Strategics, and Digital Health. At this RESI, we will be featuring two new panel topics, Women’s Health and CNS Diseases. Join our seasoned panelists from a wide range of sectors to get the latest insight on trends, emerging topics, advice, and more!

Take a look below for our panelists who will be giving you the latest scoop:

Elizabeth Bailey Managing Director RH Capital	Caleb Bell Venture Partner Corundum Systems Biology	Nat Brinn Partner VC23
Frederic Cedrone Vice President, Corporate Innovation Catalent Strategic Ventures	Geoff Dacosta Director, Business Development and Licensing Philips Healthcare	Neel Desai Business Development & Licensing Biogen
Marissa Fayer U.S. Partner Goddess Gaia Ventures	Tom Gibbs Director Debiopharm Innovation Fund	Lucio Iannone VP of Investments Leaps by Bayer
Jotthe Kannappan Associate Intuitive Surgical	Arianne Kidder Principal Seae Ventures	Joan Koerber-Walker Co-Founder and Managing Member AZBio
Adam Kundzewicz Executive Director Boehringer Ingelheim Venture Fund	Linda Li Venture Partner Cleveland Clinic Ventures	Wasim Malik Co-Founder and Managing Partner Iaso Ventures
Amanda Mason Director, Global Head of Inflammation Search & Evaluation, Business Development Amgen	John Pennett Angel Investor Mid Atlantic Bio Angels	Jane Rho Investor, Venture Fund DaVita Venture Group
Ronak Savla Director, Strategic Ventures Catalent Strategic Ventures	Yaniv Sneor Founding Member Mid Atlantic Bio Angels	Ashim Subedee Director, Catalyst Office Division of Research Innovation and Ventures (DRIVe)
David Uffer Vice President, MedTech General Inception	Matt Weinberg Partner Max Ventures	Sonia Weiss Co-Founder & Managing Partner WPSS.bio
Andrew Wong Global Head of Bayer CoLabs Bayer	Lu Zhang Managing Partner Fusion Fund

By Antoinette Lowre, Manager of Business Development, LSN

The AAP is a cost-effective way to attend RESI Boston on Monday, June 5^th, and network with over 600 early-stage life science startups, investors, and strategic partners. With an AAP, you can join all the live sessions including the Innovator’s Pitch Challenge, investor panels and entrepreneur workshops. This registration option does not include partnering but allows you to take advantage of the educational component of RESI along with the collision factor we see at all our in-person events.

Check out our agenda for Monday, June 5

You can also view the investors who are attending RESI Boston June on our RESI Conference Website which we update frequently so you know who will be a good fit for you to meet in June.

Investor Panel

Innovator’s Pitch Challenge

Entrepreneur Workshop

Want to learn more about RESI and how you can take advantage of the AAP? Reach out to your BD manager and we’d love to answer any questions you may have and learn more about your startup company’s fundraising goals.

Life Science Nation Business Development Team
International	East Coast (USA) & China	Midwest (USA) & Canada	West Coast  (USA)
Greg Mannix Vice President International Business Development Book a Meeting Email Me	Candice He VP, Business Development & Global Investment Strategist Book a Meeting Email Me	Antoinette Lowre Manager of Business Development Book a Meeting Email Me	Cameron Hurlburt Manager of Business Development Book a Meeting Email Me

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

Don’t miss your chance to interact with tech hubs at RESI Boston in June. Tech hubs are a crucial part of the Life Science Nation (LSN) and RESI community as they provide capital, entrepreneurial support, lab space, and economic development for their cohort of aspiring scientist-entrepreneur and fundraising executives. With this immense support from tech hubs, their group of startups, who’ve raised less than $2M USD, can accelerate their entrepreneurship journey by participating in RESI at a discounted rate and taking advantage of LSN services. Ranging from universities, non-profits, incubators, accelerators, and regional and government organizations, they are all looking to connect with investors, strategic partners, and early-stage life science startups in Boston.

Don’t see your organization on this list? Contact us to learn more about the Super Early Bird rate and discounted sponsorship levels for your tech hub and startups.

RESI Boston June 2023 Featured Tech Hubs

By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

Life Science Nation’s second hybrid conference of this year, RESI Boston June, is taking place in person on June 5th and virtually on June 6-7th. This conference offers an excellent opportunity for early-stage life science and healthcare companies that are seeking financing to meet with investors and strategic partners.

RESI Boston June has been gaining immense interest from both US domestic and international investors. We are expecting over 350 investors to join us at this upcoming conference, including big pharma, medtech, CVCs, venture capital funds, angel groups, family offices, and more. The LSN investor research team has been busy inviting investors to this event, while making sure that their investment interest fits the company profiles at RESI, and they are actively looking for investment opportunities and partnerships in the space. This unique vetting process ensures the quality of partnering at RESI, which separates RESI from the other conferences. Through RESI’s powerful partnering platform, attendees are able to identify those that best fit their interest with ease.  Whether you represent an early-stage company, service provider or an investment firm, RESI Boston will be an incomparable opportunity to grow your network and connect with key players within the industry.

Sign up now to join the below investors at RESI Boston June, and don’t miss the deadline this Friday, April 28th, to take advantage of the Early Bird price.

RESI Boston June 2023 Confirmed Investors

*April 24, 2023

Click Here to See More Investors

Lyndsey Linke

Interview with Lyndsey Linke (PhD, M.Eng), CEO and Co-Founder of SiVEC Biotechnologies By Caitlin Dolegowski, Marketing Manager, LSN

Caitlin Dolegowski

Caiti Dolegowski (CD): Lyndsey, introduce us to SiVEC Biotechnologies and its technology.

Lyndsey Linke, PhD, M.Eng, CEO and Co-Founder of SiVEC Biotechnologies (LL): Recognized as the 2022 Top Emerging Company at BIO International, SiVEC Biotechnologies has developed BactPac™, a live biotherapeutic delivery platform to enable the next generation of nucleic acid and gene editing therapies. BactPac can both produce and deliver therapeutic payloads (mRNA, siRNA, proteins, and CRISPR/Cas) safely and precisely to a wide range of tissues and tumors that cannot be targeted by viral vectors and lipid nanoparticles. Using the BactPac platform, SiVEC is developing high-value, first-in-class assets targeting a range of therapeutic areas, including oncology, respiratory diseases, and rare genetic diseases. SiVEC has secured over $4M in federal and state funding, has a strong patent portfolio, and an early collaboration with a gene-therapy company. SiVEC’s mission is to develop advanced biologics for hard-to-treat diseases and out-license the BactPac platform to companies needing a safe, tissue-targeted method of delivery to advance nucleic acid and gene therapies into clinical stages.

CD: What stage of fundraising is SiVEC Biotechnologies in and what milestone are you working toward?

LL: SiVEC Biotechnologies is seeking a lead investor in a seed round raising $7 million to supplement NIH funding and bring our lead asset to an IND submission, advance our oncology program into IND-enabling studies, make critical hires to strengthen and build out a winning team, accelerate our pipeline development, and secure our second industry partnership.

CD: Tell us about SiVEC Biotechnologies team.

LL:  Supporting SiVEC Biotechnologies’ mission is our leadership team, with 45 years of combined experience in relevant R&D. SiVEC is led by Lyndsey Linke, PhD, ME, (CEO and co-founder) who has secured over $4M in grants and sponsored research for SiVEC, has over 18 years’ R&D experience with nucleic acid therapeutics and antivirals, and is lead inventor on 7 issued or pending patents, including the company’s core technology. Lyndsey has also been recognized as an Inspiring Female Founder, she was a former Olympic Swimming Trials qualifier and a 9X US Master’s National Champion. SiVEC’s co-founder and VP of Operations, Darcy Mora (MS), has over 14 years’ research experience, she has served as Project Lead Vaccine Developer for more than 10 global wildlife vaccines at USDA, and is an inventor on 6 issued or pending patents. SiVEC’s Director of R&D, Ash Williams (PhD), has nearly 20 years of experience as a bacterial geneticist and cell biologist and was previously faculty at the University of Cologne after completing his post-doctoral fellowships at Harvard University and the University of Southern California.  SiVEC has a deep-seated bench of advisors, with diverse expertise in biologic manufacturing, regulatory affairs, scientific and business strategy, who have held esteemed leadership positions at Boehringer Ingelheim, Roche, and AbbVie.

CD: Life Science Nation works with tech hubs to bring early-stage fundraising entrepreneurs to our RESI conferences. SiVEC Biotechnologies is a member of our associated tech hub, California Life Sciences. Is this how you learned of the RESI conference series?

LL: One of our business advisors, who is now formerly associated with California Life Sciences (CLS), had suggested we participate in the RESI 2021 virtual conference. This was a fantastic way to get introduced to potential investors, and while SiVEC was not formally raising money in 2021, participating in RESI was an opportunity to “get on the investor’s radar”. SiVEC was also a part of the Women in Bio (WIB)-FAST program, a mentoring program sponsored through CLS. As part of a WIB-FAST cohort graduate company, CLS invited SiVEC to participate in the CLS Innovation Track to pitch at RESI 2023 at JPM.  That was our first in-person experience pitching at RESI and was a catalyst for our decision to participate at the 2023 RESI March virtual conference and the Innovator’s Pitch Challenge, where we took first place. Therefore, we appreciate the sponsorship and mentoring we have received through our association with CLS over the years.

CD: SiVEC Biotechnologies has attended Life Science Nation (LSN)’s Redefining Early Stage Investment (RESI) conference series in both our digital/virtual and hybrid formats. In addition, you have the unique perspective of participating in our Innovator’s Pitch Challenge both virtually and in-person. SiVEC Biotechnologies was the first-place winner at Digital RESI March, congratulations! What worked well for you in both formats.

LL: Nothing takes the place of in-person networking and face-to-face conversations, so getting back to this format at RESI JPM in 2023 was so refreshing and reenergizing in many ways. However, most of our investor meetings at RESI/JPM were all virtual. Because of the success we had with these virtual meetings, we decided to register for the RESI and IPC virtual pitch in March. Interestingly, we had greater attendance and follow-up from our virtual pitch compared to our in-person pitch. Both formats have their advantages, and we plan on participating in future RESI conferences, regardless of whether they are virtual or in-person.

CD: Where are you now and what lessons would you pass on and what advice to other startup CEOs would you give?

LL: SiVEC Biotechnologies has gone through so much growth and technology vetting, and I’m so proud of our team and what we have accomplished and continue to demonstrate. With the recognition we’ve received from BIO, RESI, WIB, CLS, NIH, and even recognition within our local biotech ecosystem through the state of Colorado and the Colorado Bioscience Association, we have so much traction going forward. We really are a top emerging biotech company and we’re leading the charge to enable the next generation of nucleic acid and gene therapies. My advice for other companies and startup CEOs is to highlight your strengths and focus on differentiating yourself from your competitors. Tell a compelling story, make it relatable, get your audience to really understand the problem you are solving and build conviction for why your team is going to get it done.